vascular stent News
-
BioMimics 3D Vascular Stent System granted Shonin in Japan – December 2019
The BioMimics 3D Vascular Stent System received Shonin regulatory approval in Japan. On December 19th, 2019, Japanese MHLW PMDA granted Marketing Pre-Market Approval (“Shonin”) for BioMimics 3D Vascular Stent System to improve luminal diameter during endovascular intervention in patients with symptomatic peripheral arterial disease in the femoropopliteal artery. The approved ...
-
BioMimics 3D, a next generation biomimetic peripheral stent, now available nationwide with Veryan Medical and Premier collaboration
HORSHAM, UK – 01 MAY 2022 – Veryan Medical Inc. has been awarded a group purchasing agreement for Peripheral and Biliary Stents with Premier, Inc. Effective 01 May 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the BioMimics 3D Vascular Stent ...
-
First BioMimics 3D US Implant
Veryan Medical (Horsham, UK) has announced that Dr. Bret Wiechmann and his team at Vascular and Interventional Physicians in Gainesville, FL implanted the first commercial BioMimics 3D Vascular stent in the US, on the same day that the device was officially launched in the US. The BioMimics 3D self-expanding, nitinol stent features a highly differentiated, helical centre-line design that has ...
-
ASTM F2743 - 11 standard guide for coating inspection and acute particulate characterization of coated drug-eluting vascular stent systems
The shedding of the coating from a vascular stent can alter its clinical safety and/or therapeutic benefit. Clinical performance (for example, drug elution) may be affected by particulate generation from the coated stent system and coating defects. This document provides guidance for coating inspection and acute particulate characterization of drug eluting ...
-
BioMimics 3D US launch
Veryan Medical (Horsham, UK) today announced that it has launched the innovative BioMimics 3D Vascular Stent System in the US. The BioMimics 3D self-expanding, nitinol stent features a highly-differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up. 01 September 2020 Nick Yeo, Veryan’s CEO ...
-
36-month results from Veryan Medical’s MIMICS-2 study at CX 2020 Live
Professor Thomas Zeller (University Heart Centre Freiburg, Bad Krozingen, Germany) today presented the 36-month results from Veryan Medical’s MIMICS-2 study at CX 2020 Live. MIMICS-2 is a prospective, single-arm, multi-centre clinical study to evaluate the safety and effectiveness of the BioMimics 3D® Vascular Stent System in the treatment of patients with symptomatic atherosclerotic ...
-
Pathway to Solve "Aging Population Syndrome", New Hope Has Been Delivered at TEDx Event
CHENGDU, China, Sept. 7, 2017 /PRNewswire/ -- Aging and related diseases are problems we have to face. Recently, Dr. Y. James Kang, CEO/CSO of Revotek and a pathfinder in Regenerative Medicine, delivered a talk entitled "Transforming Disease-based Medication to Personalized Healthcare" at the TEDx event in Chengdu, China. He unveiled techniques that would improve the quality of life for 2 billion ...
-
Imperial Innovations Set to Increase Investment in Veryan Medical
The technology transfer, incubation and venture investment company Imperial Innovations, Veryan’s largest investor with a 44.3% shareholding, is proposing to increase its investment in the company, in order to help fund future growth… Imperial Innovations Set to Increase Investment in Veryan Medical The technology transfer, incubation and venture investment company Imperial ...
-
£1.1 million project to develop new biodegradable stents
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of ...
-
Invizius named ‘Best Innovative MedTech’
Invizius, a University of Edinburgh spinout whose technology promises to improve the lives of millions of dialysis patients, has been named Best Innovative MedTech company at the prestigious OBN Awards. The company’s success in the awards, which have a high profile in the life sciences sector, follows on from a seed investment of £500,000 from Mercia Fund Managers in May 2018. ...
-
Invizius secures £0.5m investment
A spinout company whose technology could save the lives of thousands of dialysis patients has secured £500,000 from Mercia Asset Management, in the first investment deal since Mercia’s partnership with the University of Edinburgh was announced in November 2017. Invizius stems from years of research by Invizius co-founder, Dr Andy Herbert and his team, who believe they have ...
-
Orchestra BioMed Strengthens Management Team with Appointments of Expert Product Development Leaders Juan A. Lorenzo and Paul V. Goode, Ph.D.
Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced senior-level appointments to its product development teams. Juan Lorenzo, an expert in vascular devices, joins as vice president, product development, Focal Therapies and will ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you